Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Director Sells $2,648,400.00 in Stock

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) Director Matthew K. Fust sold 60,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $44.14, for a total transaction of $2,648,400.00. Following the completion of the sale, the director now directly owns […]

Related Keywords

China ,Robertw Baird ,Matthewk Fust , ,Nasdaq ,China Universal Asset Management Co ,Institutional Investors Weigh In On Crinetics Pharmaceuticals ,Osaic Holdings Inc ,Crinetics Pharmaceuticals Stock Performance ,Crinetics Pharmaceuticals Inc ,Tower Research Capital ,Crinetics Pharmaceuticals ,Securities Exchange Commission ,Crinetics Pharmaceuticals Company Profile ,Quarter For Crinetics Pharmaceuticals ,Citigroup ,News Ratings For Crinetics Pharmaceuticals Daily ,Get Free Report ,Director Matthew ,Exchange Commission ,Universal Asset Management ,Research Capital ,Osaic Holdings ,Crinetics Pharmaceuticals Daily ,Nasdaq Crnx ,Crnx ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,